Multiple Myeloma Market - Global Market Share, Trends, Analysis and Forecast 2023 - 2032
The global multiple myeloma market size was estimated to be US$ 19.5 billion in 2020 and is expected to reach US$ 30.2 billion by 2031 at a CAGR of 4.1%.
As indicated by myeloma UK, in myeloma, plasma cells become strange, duplicate wildly and delivery just one sort of neutralizer known as para protein, which has no helpful traits present. It is not unexpected, through the figuring of this para protein, that myeloma is diagnosed and identified.
The disease happens in the bone marrow and regularly brings about broad bone annihilation with osteolytic injuries, osteopenia, and additionally fractures. Different entanglements related with the disease likewise incorporate high calcium hyperlipidemia, renal complications, frailty, and infections caused in various other organs. Multiple myeloma is a cancer of the blood segments like plasma cells, officially known as Kahler's disease.
As articulated by WHO, Cancer is a primary reason of deaths around the world, registering around 11.8 million deaths in 2020. Around the world, around 1 of every 6 deaths is because of cancer. Complications associated with treating geriatric patients are driving the demand for effective treatments, for example, rebuilding methodology including transfusion of blood components and point of care progressions.
Launching of medications each year and latest updates noted in drugs and biotechnological areas or enterprises are major aspects driving the market development. The evolution of new medications and the use of autologous hematopoietic undeveloped cell transplantation have altogether improved the diagnosis of multiple myeloma.
In any case, restricted income along with lesser financial aid combined with high treatment cost essentially and patent lapse are a portion of the eye-catching factors that are expected to hinder the development of this market during 2023-2032.
Global Multiple Myeloma Market Value Share Analysis, by Geography (2022)
The report titled “Global Multiple Myeloma Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032”, wherein 2021 is the historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the Global Multiple Myeloma Market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market.
The global Multiple Myeloma market is segmented based on type, treatment, route of administration, end-users and distribution channel, and region. Based on type, the Multiple Myeloma market is segmented into smouldering multiple myeloma and active multiple myeloma and Others. Based on treatment, the Multiple Myeloma market is segmented into chemotherapy, targeted therapy, corticosteroids, immunomodulatory agents, and Others. Based on route of administration, the Multiple Myeloma market is segmented into oral, parenteral and Others. Based on end-users, the Multiple Myeloma market is segmented into hospitals, homecare, specialty centers and Others. Based on distribution channel, the Multiple Myeloma market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy.
Based on geography, the Global Multiple Myeloma Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America is sub-segmented into the United States, Canada, and Rest of North America. Europe is sub-segmented into Germany, United Kingdom, Italy, France, Spain, and Rest of Europe. Asia Pacific is sub-segmented into China, Japan, India, Australia, and Rest of Asia Pacific. Middle East & Africa is sub-segmented into Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa. South America is sub-segmented into Brazil and Rest of South America.
The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment and would identify the segment of the company focusing on Global Multiple Myeloma Market. Further, market share of prominent companies in the Global Multiple Myeloma Market would also be estimated.
The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, swot analysis, and research and development focus of all the Multiple Myeloma companies. The Global Multiple Myeloma Market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution.
Product portfolio would focus on all the products under the Multiple Myeloma business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the Global Multiple Myeloma Market.
The key players of the Global Multiple Myeloma Market are Johnson & Johnson Services Inc, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Eagle Pharmaceuticals, Inc, Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd, Mylan N.V., Hikma Pharmaceutical Plc, Apotex Inc, Alvogen, Amneal Pharmaceutical Inc, and others.
Global Multiple Myeloma Market Key Segments:
Based on Type
- Smouldering multiple myeloma
- Active multiple myeloma
- Others
Based on Treatment Type
- Themotherapy
- Targeted therapy
- Corticosteroids
- Immunomodulatory agents
- Others
Based on Route of Administration Type
- Oral
- Parenteral
- Others
Based on End-Users Type
- Hospitals
- Homecare
- Speciality centres
- Others
Based on Distribution Channel Type
- Hospital pharmacy
- Online pharmacy
- Retail pharmacy
- Others
Based on Region
- North America
- U.S.
- Canada
- Rest of North America
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Rest of APAC
- Middle East & Africa
- UAE
- South Africa
- Saudi Arabia
- Rest of MEA
- South America
- Brazil
- Rest of South America
- Introduction
- Research Objectives
- Report Assumptions
- Research Methodology
- Abbreviations
- Preface
- Market Definition
- Report Scope and Market Segmentation
- Research Highlights
- Market Synopsis: Global Multiple Myeloma Market
- Global Multiple Myeloma Market Qualitative Analysis
- Trends
- Market trends
- Technology Trends
- PESTLE Analysis (For 3 prominent countries)
- Market Influencers
- Driving Forces
- Hindering Forces
- Opportunities
- COVID-19 impact
- Trends
- Global Multiple Myeloma Market Analysis and Forecast, by Type
- Overview and definitions
- Key segment analysis
- Global Multiple Myeloma Market Estimates (US$ Mn), by Type, 2019 – 2032
- Smouldering multiple myeloma
- Active multiple myeloma
- Others
- Global Multiple Myeloma Market Analysis and Forecast, by Treatment Type
- Overview and definitions
- Key segment analysis
- Global Multiple Myeloma Market Estimates (US$ Mn), by Treatment Type, 2019 – 2032
- Targeted Therapy
- Biologic Therapy
- Chemotherapy
- Others
- Global Multiple Myeloma Market Analysis and Forecast, by Drug Type
- Overview and definitions
- Key segment analysis
- Global Multiple Myeloma Market Estimates (US$ Mn), by Drug Type, 2019 – 2032
- Immunomodulatory Drugs
- Proteasome Inhibitors
- Histone Deacetylase Inhibitors
- Monoclonal Antibody Drugs
- Steroids
- Others
- Global Multiple Myeloma Market Analysis and Forecast, by Distribution Channel
- Overview and definitions
- Key segment analysis
- Global Multiple Myeloma Market Estimates (US$ Mn), by Distribution Channel, 2019 – 2032
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Global Multiple Myeloma Market Analysis and Forecast, by Region
- Overview and definitions
- Key segment analysis
- Global Multiple Myeloma Market Estimates (US$ Mn), by Region, 2019 – 2032
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- South America
- North America Multiple Myeloma Market Analysis and Forecast
- Overview and definitions
- Key segment analysis
- North America Multiple Myeloma Market Estimates (US$ Mn), by Type, 2019 – 2032
- Smouldering multiple myeloma
- Active multiple myeloma
- Others
- North America Multiple Myeloma Market Estimates (US$ Mn), by Treatment Type, 2019 – 2032
- Targeted Therapy
- Biologic Therapy
- Chemotherapy
- Others
- North America Multiple Myeloma Market Estimates (US$ Mn), by Drug Type, 2019 – 2032
- Immunomodulatory Drugs
- Proteasome Inhibitors
- Histone Deacetylase Inhibitors
- Monoclonal Antibody Drugs
- Steroids
- Others
- North America Multiple Myeloma Market Estimates (US$ Mn), by Distribution Channel, 2019 – 2032
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- North America Multiple Myeloma Market Estimates (US$ Mn), Country, 2019 – 2032
- United States
- Canada
- Rest of North America
- Europe Multiple Myeloma Market Analysis and Forecast
- Overview and definitions
- Key segment analysis
- Europe Multiple Myeloma Market Estimates (US$ Mn), by Type, 2019 – 2032
- Smouldering multiple myeloma
- Active multiple myeloma
- Others
- Europe Multiple Myeloma Market Estimates (US$ Mn), by Treatment Type, 2019 – 2032
- Targeted Therapy
- Biologic Therapy
- Chemotherapy
- Others
- Europe Multiple Myeloma Market Estimates (US$ Mn), by Drug Type, 2019 – 2032
- Immunomodulatory Drugs
- Proteasome Inhibitors
- Histone Deacetylase Inhibitors
- Monoclonal Antibody Drugs
- Steroids
- Others
- Europe Multiple Myeloma Market Estimates (US$ Mn), by Distribution Channel, 2019 – 2032
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Europe Multiple Myeloma Market Estimates (US$ Mn), Country, 2019 – 2032
- Germany
- United Kingdom
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific Multiple Myeloma Market Analysis and Forecast
- Overview and definitions
- Key segment analysis
- Asia Pacific Multiple Myeloma Market Estimates (US$ Mn), by Type, 2019 – 2032
- Smouldering multiple myeloma
- Active multiple myeloma
- Others
- Asia Pacific Multiple Myeloma Market Estimates (US$ Mn), by Treatment Type, 2019 – 2032
- Targeted Therapy
- Biologic Therapy
- Chemotherapy
- Others
- Asia Pacific Multiple Myeloma Market Estimates (US$ Mn), by Drug Type, 2019 – 2032
- Immunomodulatory Drugs
- Proteasome Inhibitors
- Histone Deacetylase Inhibitors
- Monoclonal Antibody Drugs
- Steroids
- Others
- Asia Pacific Multiple Myeloma Market Estimates (US$ Mn), by Distribution Channel, 2019 – 2032
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Asia Pacific Multiple Myeloma Market Estimates (US$ Mn), Country, 2019 – 2032
- Japan
- India
- China
- Australia
- Rest of Asia Pacific
- Middle East & Africa Multiple Myeloma Market Analysis and Forecast
- Overview and definitions
- Key segment analysis
- Middle East & Africa Multiple Myeloma Market Estimates (US$ Mn), by Type, 2019 – 2032
- Smouldering multiple myeloma
- Active multiple myeloma
- Others
- Middle East & Africa Multiple Myeloma Market Estimates (US$ Mn), by Treatment Type, 2019 – 2032
- Targeted Therapy
- Biologic Therapy
- Chemotherapy
- Others
- Middle East & Africa Multiple Myeloma Market Estimates (US$ Mn), by Drug Type, 2019 – 2032
- Immunomodulatory Drugs
- Proteasome Inhibitors
- Histone Deacetylase Inhibitors
- Monoclonal Antibody Drugs
- Steroids
- Others
- Middle East & Africa Multiple Myeloma Market Estimates (US$ Mn), by Distribution Channel, 2019 – 2032
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Middle East & Africa Multiple Myeloma Market Estimates (US$ Mn), Country, 2019 – 2032
- Saudi Arabia
- UAE
- South Africa
- Rest of Middle East
- South America Multiple Myeloma Market Analysis and Forecast
- Overview and definitions
- Key segment analysis
- South America Multiple Myeloma Market Estimates (US$ Mn), by Type, 2019 – 2032
- Smouldering multiple myeloma
- Active multiple myeloma
- Others
- South America Multiple Myeloma Market Estimates (US$ Mn), by Treatment Type, 2019 – 2032
- Targeted Therapy
- Biologic Therapy
- Chemotherapy
- Others
- South America Multiple Myeloma Market Estimates (US$ Mn), by Drug Type, 2019 – 2032
- Immunomodulatory Drugs
- Proteasome Inhibitors
- Histone Deacetylase Inhibitors
- Monoclonal Antibody Drugs
- Steroids
- Others
- South America Multiple Myeloma Market Estimates (US$ Mn), by Distribution Channel, 2019 – 2032
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- South America Multiple Myeloma Market Estimates (US$ Mn), Country, 2019 – 2032
- Brazil
- Rest of South America
- Competition Analysis – Multiple Myeloma Market
- Market Composition
- Market Share Analysis (%), by Supplier (2022)
- Company Profiles
- Amgen Inc.
- Business overview
- Geographic presence
- Product portfolio
- Financial facts
- Relevant news and strategic view
- Bristol Myers Squibb
- Daiichi Sankyo Co., Ltd.
- Sanofi-Aventis Groupe
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novartis International AG
- Pfizer Inc.
- PHARMA MAR, S.A.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Amgen Inc.
- Conclusion & Recommendations
Frequently asked questions about this report
How big is the multiple myeloma market?
The global multiple myeloma market was worth US$ 19.5 billion in 2020.
What is the estimated growth rate of multiple myeloma market?
The global multiple myeloma market is expected to register a CAGR of 4.1% forecast to 2031.
What are the growth estimates for multiple myeloma market till 2031?
The global multiple myeloma market is estimated to surpass US$ 30.2 Billion by 2031.
What are the factors driving the multiple myeloma market?
Launching of medications each year and latest updates noted in drugs and biotechnological areas or enterprises are major aspects driving the multiple myeloma market development.
What are the different types of multiple myeloma used?
Based on type, the multiple myeloma market is segmented into Smouldering and Active.
Which prime multiple myeloma players are profiled in this analysis?
Key multiple myeloma market players are Johnson & Johnson Services Inc, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Eagle Pharmaceuticals, Inc, Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd and others.